Evidence map›Paper›PMID 40823489›Full record

ArticleRSC medicinal chemistry2025

Structural insights into the nirmatrelvir-resistant SARS-CoV-2 M

Conrad Fischer, Jimmy Lu, Marco J van Belkum, Sydney Demmon, Pu Chen, Chaoxiang Wang, Tayla J Van Oers, Tess Lamer, M Joanne Lemieux, John C Vederas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Conrad FischerDepartment of Chemistry, University of Alberta Edmonton AB T6G 2G2 Canada john.vederas@ualberta.ca.ORCID https://orcid.org/0000-0002-2289-010X
Jimmy LuDepartment of Biochemistry, Li Ka Shing Institute of Virology, University of Alberta Edmonton T6G 2E1 AB Canada.ORCID https://orcid.org/0000-0002-4090-5176
Marco J van BelkumDepartment of Chemistry, University of Alberta Edmonton AB T6G 2G2 Canada john.vederas@ualberta.ca.ORCID https://orcid.org/0000-0002-9296-6069
Sydney DemmonDepartment of Biochemistry, Li Ka Shing Institute of Virology, University of Alberta Edmonton T6G 2E1 AB Canada.
Pu ChenDepartment of Biochemistry, Li Ka Shing Institute of Virology, University of Alberta Edmonton T6G 2E1 AB Canada.
Chaoxiang WangDepartment of Chemistry, University of Alberta Edmonton AB T6G 2G2 Canada john.vederas@ualberta.ca.
Tayla J Van OersDepartment of Chemistry, University of Alberta Edmonton AB T6G 2G2 Canada john.vederas@ualberta.ca.ORCID https://orcid.org/0009-0006-2314-560X
Tess LamerDepartment of Chemistry, University of Alberta Edmonton AB T6G 2G2 Canada john.vederas@ualberta.ca.ORCID https://orcid.org/0000-0002-1511-4540
M Joanne LemieuxDepartment of Biochemistry, Li Ka Shing Institute of Virology, University of Alberta Edmonton T6G 2E1 AB Canada.ORCID https://orcid.org/0000-0003-4745-9153
John C VederasDepartment of Chemistry, University of Alberta Edmonton AB T6G 2G2 Canada john.vederas@ualberta.ca.ORCID https://orcid.org/0000-0002-2996-0326

Funding

A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
NIGMS NIH HHS P30 GM133894
6 · The paper itself

Abstract

Drug-resistance is an eminent threat in antiviral therapy, and is currently a concern in nirmatrelvir-based therapy of SARS-CoV-2. Nirmatrelvir (antiviral component in Paxlovid) binds covalently to the active site cysteine of the main protease of SARS-CoV-2 (M

Identifiers

PMID40823489
PMCPMC12356143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.